רנוולה  טבליות 800 מג ישראל - עברית - Ministry of Health

רנוולה טבליות 800 מג

sanofi israel ltd - sevelamer carbonate anhydrous - טבליות מצופות פילם - sevelamer carbonate anhydrous 800 mg - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

קימריה ישראל - עברית - Ministry of Health

קימריה

novartis israel ltd - tisagenlecleucel - tisagenlecleucel

אפמודי 10 מג ישראל - עברית - Ministry of Health

אפמודי 10 מג

medomie pharma ltd, israel - hydrocortisone - hydrocortisone 10 mg - hydrocortisone

אפמודי 5 מג ישראל - עברית - Ministry of Health

אפמודי 5 מג

medomie pharma ltd, israel - hydrocortisone - hydrocortisone 5 mg - hydrocortisone

ארטרוטק 75 ישראל - עברית - Ministry of Health

ארטרוטק 75

pfizer pharmaceuticals israel ltd - diclofenac sodium 75 mg; misoprostol 200 mcg - tablets - diclofenac - for patients requiring longterm anti-inflammatory treatment, in such circumstances where there is a high risk of developing hemorrhage or ulcer i.e. patients with a peptic ulcer or past gastric bleeding, patients with cardiovascular disease, patients over 65 and smokers.

קסינתה 500 יחבל ישראל - עברית - Ministry of Health

קסינתה 500 יחבל

pfizer pharmaceuticals israel ltd - moroctocog alfa - אבקה מיובשת בהקפאה להזרקה - moroctocog alfa 500 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)

קסינתה 1000 יחבל ישראל - עברית - Ministry of Health

קסינתה 1000 יחבל

pfizer pharmaceuticals israel ltd - moroctocog alfa - אבקה וממס להכנת תמיסה להזרקה - moroctocog alfa 1000 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)

קסינתה 2000 יחבל ישראל - עברית - Ministry of Health

קסינתה 2000 יחבל

pfizer pharmaceuticals israel ltd - moroctocog alfa - אבקה וממס להכנת תמיסה להזרקה - moroctocog alfa 2000 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)

בנפיקס 250 יח' בינל ישראל - עברית - Ministry of Health

בנפיקס 250 יח' בינל

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 250 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

בנפיקס 500 יח' בינל ישראל - עברית - Ministry of Health

בנפיקס 500 יח' בינל

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 500 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup).benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.